Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q2 FY2027 Earnings Presentation
34 slides from Poly Medicure's earnings presentation, Nov 5, 2026
Slide 1: Submission of Investor's Presentation to stock exchanges
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA) ) :» IPOLYMED T: +91 -11- 33550700, 47317000 E: [email protected] W: polymedicure.com CIN : L40300DL1995PLC066923 Date: osu, November, 2026 Scrip Code: - 531768 Seri p Code:- POL
Slide 2: Investor Presentation: Q2 & H1 FY27
Investor Presentation : Q2 & H1 FY27 Nov 5, 2026 1
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Company Overview
Company Overview
Slide 5: Polymed at a Glance
Polymed at a Glance Largest* Listed Medical Devices Player in India | Largest Exporter of Medical Consumables Figs in Rs. Crs unless specified PRODUCT PORTFOLIO Infusion 15 225+ 125+ Therapy Safety IV Cannula Prefilled Saline Needle Free Three Way Stop Cock Closed Wound Endotracheal Fistula Cannula
Slide 6: Polymed Flywheel
Polymed Flywheel Integrated business model serving customers globally Clinical Engagement In-House Product R&D • 60+ clinical experts; • 25-30 new product launches annually • 4,000+ annual customer • 90+ R&D professionals engagement programs globally Distribution Network Manufacturing, Packaging and
Slide 7: Diversified Segment and Geographic Mix
Diversified Segment and Geographic Mix Rising contribution from New Segments | Deepening Presence in the Indian Market Segmental Revenue Mix Figs in Rs. Crs unless specified PORTFOLIO MIX Particulars FY23 FY24 FY25 FY26 CAGR (23-26) 24% 37% Infusion Therapy 771 925 1,012 997 9% 7% 10% Renal 76 94 15
Slide 8: Moving up the value Chain
Moving up the value Chain From essential consumables to advanced Medical Technologies • Acquired Citieffe • Entered cardiology in 2024 • Over time to create a • Launched DES in India in 2025 comprehensive portfolio • Initiated a 2000 patient clinical trial in India and Europe in 2025 Focused on prod
Slide 9: A 30-year compounding story – Growth Engine Just warming up
A 30-year compounding story – Growth Engine Just warming up Proven yesterday. Scaling today. Defining tomorrow. P O L Y MED 1.0 P O LYMED 2.0 P O LYMED 3.0 Foundation Inflection Ascent FY 1996–2020 FY 2021–2026 FY 2027 onwards • IPO 1996 (~Rs 5.4 Cr)* • First Institutional Raise • Unlocking value vi
Slide 10: Polymed 1.0 (1996 to 2020): Foundation
Polymed 1.0 (1996 to 2020): Foundation Resiliently built a global medical device platform with equity infusion of ~INR 54mn* ~25 years | Dedicated Focus | Bootstrapped From ~INR 5.4 Cr* IPO in 1996 built a globally competent infusion therapy platform Growth Funded by Internal Accruals Manufacturing
Slide 11: Polymed 2.0 (2021 to 2026): Inflection
Polymed 2.0 (2021 to 2026): Inflection The inflection: capital, capacity, categories, countries — all scaling in parallel INR 14 Bn Institutional Equity Raised | Portfolio Expansion Growth Capital utilized towards capacity expansion, deeper penetration in Renal & Critical Care, alongside venturing i
Slide 12: Polymed 3.0 (2027 onwards): Ascent
Polymed 3.0 (2027 onwards): Ascent The next chapter isn’t incremental - it’s exponential ! 2.0x Revenue | Industry-leading margins | Globalization of the Business Model Climb the Tech Ladder Business Expansion • Double R&D spend • 2 upcoming plants • Globalize high-complexity verticals — • Infrastru
Slide 13: Plan1Health – Oncology focused Platform in Europe
Plan1Health – Oncology focused Platform in Europe Since 1995 | Italy | Acquired 100.0% in 2019 | EV ~Euro 4.2 Mn 1 WHAT WE ACQUIRED? 2 WHY WE ACQUIRED? 3 SYNERGIES REALISED ▪ Entry into Critical Care segment ▪ Integrated developer & seller of 2.2x 6.4x +890BPS ▪ Access to clinical data and technolog
Slide 14: PendraCare Group – Unique Cardiology Catheter Platform
PendraCare Group – Unique Cardiology Catheter Platform Since 2011 | Netherlands | Acquired 90.0% in 2025 | EV : Euro 18.8 Mn 50+ 50+ 1,150 m² 3,800 m² 1.5M+ 65+ Countries Distributors Cleanroom 3 Leased Facilities Capacity/year Employees A Unique & One of the few ACQUISITION RATIONALE independent bi
Slide 15: Citieffe - Fully integrated supplier of high-quality Trauma Implants
Citieffe - Fully integrated supplier of high-quality Trauma Implants Since 1962 | Italy | Acquired 100.0% in 2025 | EV ~Euro 31.0 Mn 30+ 25+ 45 2,100 m² 85.0%+ 90+ Countries Distributors Patents 2 manufacturing Sales from countries Employees facilities with direct presence R&D (5) & KOL (50+) A full
Slide 16: Robust Financial Performance
Robust Financial Performance Margin% Revenue from operations (INR Cr) Gross Profit (INR Cr) 68.2% 1,875 66.7% 1,670 64.9% 1,278 1,376 63.6% 1,114 1,115 893 709 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Operating EBITDA (INR Cr) PAT (INR Cr) 700 27.5% 24.4% 19.2% 16.1% 500 600 26.2% 18.0% 23.9% 459 458
Slide 17: Strong Promoters and Experienced Leadership Team
Strong Promoters and Experienced Leadership Team Promoters Experienced Leadership Team Mr. Himanshu Baid Mr. Alessandro Balboni Mr. Sujit Gupta (Managing Director) (Non-Executive Non-Independent Director) (Senior Vice President & Head International Co-founder of Poly Medicure, Mr. Baid has over Mr.
Slide 18: Robust Governance Framework
Robust Governance Framework Non-Executive Board Mr. Devendra Raj Mehta Mr. Vishal Gupta (Chairman, Non-Executive Non-Independent Director) (Non-Executive Independent Director) A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta Mr. Vishal Gupta is the Managing Director of Ashiana Housing L
Slide 19: Awards & Accolades
Awards & Accolades Mr Himanshu Baid- Visionary Mr Rishi Baid- Healthcare Leader Himanshu Baid, MD, Poly Himanshu Baid, MD, Poly Service Provider of the Year – Healthcare Entrepreneurship of the Year by India HealthNext Medicure, Healthcare Medicure Healthcare Medical Devices Award by ET Award by AHP
Slide 20: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World SCOPE 2 EMISSIONS ➢ Reduced approx. 2,998.31 tCO2e of Scope 2 emissions ENVIRONMENTAL MANAGEMENT ENERGY CONSUMPTION SYSTEM ➢ Approximately 25.44% of total energy ➢ Approx. 70% facilities are certified under consumption sourced from renewable ISO 14001:20
Slide 21: Financial Results & Key Updates – Q2 & H1 FY27
Financial Results & Key Updates – Q2 & H1 FY27
Slide 22: Key Updates
Key Updates ▪ Medyneo (Subsidiary in Brazil) operationalisation on track; first shipment dispatched in October ▪ Established a direct UK presence to capture opportunities under the India–UK FTA Key Business ▪ Clinical deployment is improving month on month: DES ~18K units (Oct 2026),Intravascular Li
Slide 23: Standalone Financial Performance Summary Q2 & H1 FY27
Standalone Financial Performance Summary Q2 & H1 FY27 Figs in Rs. Crs unless specified Margin,% Revenue Gross Profit Operating EBITDA1 69.7% 68.9% 26.7% 27.4% 17.2% 15.8% 20.3% Q2 FY27 488.3 336.3 133.9 416.5 111.3 290.5 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Revenue Gross Profit Operating
Slide 24: Consolidated Financial Performance Summary Q2 & H1 FY27
Consolidated Financial Performance Summary Q2 & H1 FY27 Figs in Rs. Crs unless specified Acquisition Impact Margin,% Revenue Gross Profit Operating EBITDA1 69.4% 70.1% 26.1% 24.0% 30.8% 32.0% 20.1% Q2 FY27 580.5 406.9 139.1 443.9 66.1 308.2 115.8 1.6 514.4 442.3 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY
Slide 25: Financial Performance Analysis
Financial Performance Analysis
Slide 26: Standalone Financial Performance Summary
Standalone Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q2 FY27 Q2 FY26 YoY Growth % H1 FY27 H1 FY26 YoY Growth % Revenue from Operations 488.3 416.5 17.2% 919.4 800.6 14.8% - Domestic 171.8 140.9 22.0% 317.8 266.5 19.3% - International 313.1 272.9 14.7% 595.0 528.8 12.
Slide 27: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q2 FY27 Q2 FY26 YoY Growth % H1 FY27 H1 FY26 YoY Growth % Revenue from Operations 580.5 443.9 30.8% 1,105.9 847.1 30.6% - Domestic 171.8 140.9 22.0% 317.8 266.5 19.3% - International 405.3 300.3 35.0% 781.5 575.4
Slide 28: Consolidated Sales Performance Analysis (1/2)
Consolidated Sales Performance Analysis(1/2) Figs in Rs. Crs unless specified Consolidated Organic Particulars Q2 FY27 Q2 FY26 YoY Growth % Q2 FY27 YoY Growth % Domestic 171.8 140.9 22.0% 171.8 22.0% International 405.3 300.3 35.0% 339.2 13.6% Other Operating Revenue 3.3 2.8 18.4% 3.3 18.4% Total Op
Slide 29: Consolidated Sales Performance Analysis (2/2)
Consolidated Sales Performance Analysis(2/2) Figs in Rs. Crs unless specified Consolidated Organic Particulars H1 FY27 H1 FY26 YoY Growth % H1 FY27 YoY Growth % Domestic 317.8 266.5 19.3% 317.8 19.3% International 781.5 575.4 35.8% 643.1 12.1% Other Operating Revenue 6.6 5.2 26.4% 6.6 26.4% Total Op
Slide 30: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Consolidated Particulars Q2 FY27 Q2 FY26 YoY Growth % H1 FY27 H1 FY26 YoY Growth % Infusion Therapy 283.7 254.1 11.7% 541.6 487.4 11.1% Orthopaedics 42.7 - NA 91.9 - NA Renal 50.6 42.3 19.6% 93.8 87.2 7.5% Cardiology 27.0 6.7 3
Slide 31: Balance Sheet Summary and Working Capital Analysis
Balance Sheet Summary and Working Capital Analysis Figs in Rs. Crs unless specified Figs in Rs. Crs unless specified Consolidated As at Sep 30, As at Mar 31, Particulars 2026 2026 Particulars As at Sep 30, 2026 As at March 31, 2026 Debtors 559 531 Total Shareholders Funds 3,307.7 3,149.2 Equity Shar
Slide 32: Cash Flow Summary
Cash Flow Summary Figs in Rs. Crs unless specified Particulars H1 FY27 EBITDA 265.7 Other operating income and non cash expense 36.2 Tax Paid (49.7) Operating Cash Flow before WC Changes 252.3 Investment in Working Capital Changes in Inventory (78.3) Changes in Debtors (39.7) Changes in Payables 10.
Slide 33: Shareholding Pattern as on 30th Sep 2026
Shareholding Pattern as on 30th Sep 2026 Top 10 Institutional Shareholders Bodies Corporate, Sr. No Name % Shareholding 2.99% Individual, 13.18% 1 Quant Mutual Fund 4.6% Any Other, 0.16% 2 Lighthouse 2.3% AIF, 3 Axis Max Life Insurance 2.1% 3.80% Insurance 4 UTI Asset Management 1.9% Companies, 2.33
Slide 34: Thank You
Thank YouThank You For any investor related queries reach us at: [email protected]